This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)

Number of Products under Development for Primary Immune Deficiency (PID), H2 2015Number of Products under Development for Primary Immune Deficiency (PID) - Comparative Analysis, H2 2015Number of Products under Development by Companies, H2 2015Number of Products under Investigation by Universities/Institutes, H2 2015Comparative Analysis by Late Stage Development, H2 2015Comparative Analysis by Clinical Stage Development, H2 2015Assessment by Monotherapy Products, H2 2015Assessment by Combination Products, H2 2015Number of Products by Targets, H2 2015Number of Products by Stage and Targets, H2 2015Number of Products by Mechanism of Actions, H2 2015Number of Products by Stage and Mechanism of Actions, H2 2015Number of Products by Routes of Administration, H2 2015Number of Products by Stage and Routes of Administration, H2 2015Number of Products by Molecule Types, H2 2015Number of Products by Stage and Top 10 Molecule Types, H2 2015